Aurobindo Pharma Forms New Subsidiary in Chile

Aurobindo Pharma experienced an increase of 1.14%, reaching Rs 1,113.55, following the establishment of a new wholly owned subsidiary in Chile, named Eugia Pharma Chile SpA, by its wholly owned step-down subsidiary, Eugia Pharma B.V. The newly established entity is intended to enhance Aurobindo Pharma's pharmaceutical product operations in Chile. The company has indicated that no governmental or regulatory approvals were necessary for this incorporation.

The subsidiary has been set up with an initial share capital of CLP 1,000,000 (approximately USD 1,050), which is divided into 100 shares, each with a nominal value of CLP 10,000. Eugia Pharma B.V. has fully subscribed to the share capital in cash, thus retaining complete ownership of the Chilean subsidiary.

Also Read: Alembic Pharma Receives USFDA Approval for Injectable Drug

Aurobindo Pharma primarily focuses on the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and associated services. Despite a 4.5% rise in revenue from operations to Rs 7,791.77 crore in Q1 FY26 compared to Q1 FY25, the company's consolidated net profit fell by 10.3% to Rs 824.75 crore.

Aurobindo Pharma is engaged in the development, manufacturing, and commercialization of a diverse array of generic pharmaceuticals, active pharmaceutical ingredients (API), and injectables across more than 150 countries. With operations spanning over 29 commercial manufacturing and packaging facilities globally, Aurobindo Pharma has received approvals from prestigious regulatory bodies, including the USFDA, UK MHRA, EDQM, PMDA Japan, Health Canada, MCC South Africa, and ANVISA Brazil.

By utilizing our strong in-house R&D capabilities, we efficiently file patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs), and formulation dossiers on a global scale.